Economic value of anti-CD20 therapies in multiple sclerosis: a systematic review of cost-effectiveness studies.

Heinemann J, Zirkel M, Schoeffski O, Dersch R, Wiendl H

Open source

DOI
10.1177/17562864261426816
Published
2026
Container
Therapeutic advances in neurological disorders
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1177/17562864261426816,
  title = {Economic value of anti-CD20 therapies in multiple sclerosis: a systematic review of cost-effectiveness studies.},
  author = {Heinemann J and Zirkel M and Schoeffski O and Dersch R and Wiendl H},
  year = {2026},
  journal = {Therapeutic advances in neurological disorders},
  doi = {10.1177/17562864261426816},
  url = {https://doi.org/10.1177/17562864261426816}
}

RIS

TY  - JOUR
TI  - Economic value of anti-CD20 therapies in multiple sclerosis: a systematic review of cost-effectiveness studies.
AU  - Heinemann J
AU  - Zirkel M
AU  - Schoeffski O
AU  - Dersch R
AU  - Wiendl H
PY  - 2026
JO  - Therapeutic advances in neurological disorders
DO  - 10.1177/17562864261426816
UR  - https://doi.org/10.1177/17562864261426816
ER  - 

APA

J, H., M, Z., O, S., R, D., & H, W. (2026). Economic value of anti-CD20 therapies in multiple sclerosis: a systematic review of cost-effectiveness studies.. Therapeutic advances in neurological disorders. https://doi.org/10.1177/17562864261426816

Source records